Name:
ZepzelcaTM (lurbinectedin: development of innovative drugs through marine organisms)

Developed by:
PHARMAMAR, SPAIN

Country(ies) involved:
Spain

Funding sources:
National

General idea:
Zepzelca (lurbinectedin), also known as PM1183, is an analog of the marine compound ET-736 isolated from the sea squirt Ecteinacidia turbinata in which a hydrogen atom has been replaced by a methoxy group.

Description:
Zepzelca is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. Together with its effect on cancer cells, lurbinectedin inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor. Transcriptional addiction is an acknowledged target in those diseases, many of them lacking other actionable targets.

Clinical studies with Lurbinectedin in clinicaltrials.gov and in clinicaltrialsregister.eu

TRL:
9. Actual system proven in operational environment

IPR involved:
Yes

Sources:
https://pharmamar.com/science-and-innovation/oncology-pipeline/?lang=en